Tekmira Pharmaceuticals Corporation's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02)
Published: Nov 11, 2013
VANCOUVER, British Columbia, Nov. 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) presented positive results from its Phase II clinical trial with patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology. The program represents the most clinically advanced application of Tekmira's proprietary LNP delivery technology.
Help employers find you! Check out all the jobs and post your resume.